Oncology

Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

Condition:   Non Small Cell Lung Cancer
Interventions:   Diagnostic Test: Pre-Treatment Biopsy;   Diagnostic Test: On-Treatment Biopsy;   Diagnostic Test: Biopsy at Disease Progression;   Diagnostic Test: Peripheral Blood-Based Studies
Sponsors:   Memorial Sloan Kettering Cancer Center;   Wang Initiative in Lung Cancer Clinical Trials
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 24, 2019 / by / in
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Conditions:   Solid Tumor;   Lymphoma
Interventions:   Drug: TTX-030;   Drug: Pembrolizumab;   Drug: Docetaxol;   Drug: Gemcitabine;   Drug: nab paclitaxel
Sponsor:   Tizona Therapeutics, Inc
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 22, 2019 / by / in
Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors

Conditions:   Lung Atypical Carcinoid Tumor;   Lung Typical Carcinoid Tumor;   Metastatic Pancreatic Neuroendocrine Tumor
Interventions:   Biological: Incomplete Freund’s Adjuvant;   Drug: Octreotide Acetate;   Biological: Sargramostim;   Biological: SVN53-67/M57-KLH Peptide Vaccine
Sponsors:   Roswell Park Cancer Institute;   NeuroEndocrine Tumor Research Foundation (NETRF);   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 21, 2019 / by / in
Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

Conditions:   Breast Cancer;   Triple Negative Breast Cancer
Interventions:   Drug: Durvalumab;   Radiation: Radiation Therapy;   Drug: Carboplatin;   Drug: Paclitaxel
Sponsors:   Cedars-Sinai Medical Center;   AstraZeneca
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 18, 2019 / by / in
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Conditions:   Breast Cancer;   Hormone Receptor Positive Tumor
Interventions:   Drug: Durvalumab;   Drug: Anastrozole 1mg;   Drug: Letrozole 2.5mg;   Drug: Exemestane 25 MG
Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   AstraZeneca
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 17, 2019 / by / in
Atorvastatin in Treating Patients With Stages IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy

Conditions:   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Stage IIB Breast Cancer AJCC v6 and v7;   Stage III Breast Cancer AJCC v7;   Stage IIIA Breast Cancer AJCC v7;   Stage IIIB Breast Cancer AJCC v7;   Stage IIIC Breast Cancer AJCC v7;   Triple-Negative Breast Carcinoma
Interventions:   Drug: Atorvastatin;   Drug: Capecitabine
Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

March 16, 2019 / by / in